Diurnal Group (LON:DNL) announced its earnings results on Monday. The company reported GBX (12.70) (($0.18)) earnings per share (EPS) for the quarter, Bloomberg Earnings reports.
Diurnal Group (LON DNL) traded down GBX 15 ($0.21) during trading hours on Wednesday, reaching GBX 199 ($2.75). The company had a trading volume of 11,715 shares, compared to its average volume of 5,226. The firm has a market capitalization of $185.23 and a price-to-earnings ratio of -995.00. Diurnal Group has a 52-week low of GBX 118 ($1.63) and a 52-week high of GBX 215.80 ($2.98).
Separately, Numis Securities reaffirmed a “buy” rating and set a GBX 185 ($2.56) target price on shares of Diurnal Group in a research report on Monday, December 18th.
About Diurnal Group
Diurnal Group plc is a clinical-stage pharmaceutical company. The Company is engaged in developing hormone therapeutics to aid treatment for various endocrine conditions. The Company’s products include Chronocort, which is engaged in developing hydrocortisone product for the treatment of congenital adrenal hyperplasia and adrenal insufficiency; Infacort, which is engaged in creating paediatric hydrocortisone replacement product for neonates and infants suffering from adrenal insufficiency; Native Oral Testosterone, which is engaged in creating oral testosterone treatment for hypogonadism, and Tri4Combi, which is engaged in developing combination therapy product of thyroid hormones for patients suffering from hypothyroidism.
Receive News & Ratings for Diurnal Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diurnal Group and related companies with MarketBeat.com's FREE daily email newsletter.